GEN - Genetic Engineering and Biotechnology News

Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney Diseases

Eli Lilly has expanded its genetic medicines pipeline and capabilities, agreeing to partner with Ascidian Therapeutics to develop RNA exon editors intended to treat inherited kidney diseases, through ...
PharmExec

Ascidian and Eli Lilly Enter $1.9 Billion Global Research Collaboration to Develop RNA Exon Editors

RNA exon editing enables replacement of multiple entire exons at kilobase scale, potentially addressing large genes and high ...

Ascidian and Lilly Enter Global Research Collaboration to Develop RNA Exon Editors for Devastating Kidney Diseases

Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced a global ...
WGHP

Exon 20: What You Need to Know About this Rare Form of Lung Cancer

CHICAGO, March 13, 2023 /PRNewswire/ -- Lung cancer is the leading cause of cancer deaths in the United States, but advancements in research and treatment are leading to improved survival rates. The ...
ascopubs.org

Identification of Recurrent Insertions and Deletions in Exon 18 and 19 of Human Epidermal Growth Factor Receptor 2 as Potential Drivers in Non–Small-Cell Lung Cancer and ...

Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer Patients with ...
EurekAlert!

Poziotinib is active in EGFR exon 20 mutant non-small cell lung cancer with efficacy highly dependent on insertion location

HOUSTON ― A Phase II clinical trial of poziotinib for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 mutations, led by researchers at The University of Texas ...